Chronic Obstructive Pulmonary Disease, COPD Clinical Trial
Official title:
A Phase 3b, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study to Compare Once Daily Nebulized Revefenacin With Spiriva Once Daily Delivered Via the HandiHaler® on Lung Function in Subjects With COPD and a Low PIFR
This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak Inspiratory Flow Rate.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00108823 -
The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)
|
Phase 3 | |
Completed |
NCT03064113 -
Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Completed |
NCT00496470 -
Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.
|
Phase 4 | |
Completed |
NCT02442206 -
Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients
|
Phase 4 | |
Completed |
NCT02615795 -
Tele Health Monitoring Service for Patients With Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02449018 -
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
|
Phase 2 |